<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394624</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16525</org_study_id>
    <secondary_id>2019-003914-15</secondary_id>
    <secondary_id>U1111-1244-1585</secondary_id>
    <nct_id>NCT04394624</nct_id>
  </id_info>
  <brief_title>SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)</brief_title>
  <acronym>CARMEN-LC04</acronym>
  <official_title>Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of SAR408701 Used in Combination With Ramucirumab in Metastatic, Non-squamous, Non-small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      o Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of
      SAR408701 in combination with ramucirumab in the NSQ NSCLC population.

      o Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in
      the NSQ NSCLC population.

      Secondary Objectives:

        -  To assess the safety and tolerability of SAR408701 in combination with ramucirumab

        -  To assess the durability of the response to treatment with SAR408701 in combination with
           ramucirumab

        -  To assess efficacy of SAR408701 in combination with ramucirumab on progression free
           survival

        -  To assess the pharmacokinetic (PK) profile of SAR408701 and ramucirumab when given in
           combination

        -  To assess the immunogenicity of SAR408701 when given in combination with ramucirumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The expected duration of the study intervention for participants may vary, based on
      progression date ; median expected duration of study per participant is estimated 11 months
      (up to 1 month for screening, a median of 6 months for treatment, and a median of 4 months
      for end-of-treatment assessments and safety follow-up visit)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 24, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of study drug-related dose-limiting toxicity (DLT) at Cycle 1 and Cycle 2</measure>
    <time_frame>baseline up to Cycle 2 (approximatively 1 month)</time_frame>
    <description>Drug-related dose-limiting toxicity (DLT) as observed during DLT-observation period tolerability in order to confirm the recommended dose of SAR408701 in combination with ramucirumab for the Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective response rate</measure>
    <time_frame>Baseline up to 6 months after the last patient treated</time_frame>
    <description>Objective response rate defined as proportion of participants with confirmed complete response (CR) or partial response (PR) as best overall response determined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline up to 90 days after the last study treatment administration</time_frame>
    <description>Incidence of TEAEs and SAEs and laboratory abnormalities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Baseline up to 6 months after the last patient treated</time_frame>
    <description>Duration of response (DOR) is defined as the time from first documented evidence of CR or PR until progressive disease (PD) determined per RECIST v.1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline up to 6 months after the last patient treated</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from the first investigational medicinal product (IMP) administration to the date of the first documented disease progression or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Cmax of SAR408701</measure>
    <time_frame>Cycle 1 (each cycle = 2 weeks)</time_frame>
    <description>Maximum concentration (Cmax) of SAR408701 observed after SAR408701 1st infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - AUC0-14d of SAR408701</measure>
    <time_frame>Cycle 1 (each cycle=2 weeks)</time_frame>
    <description>Area under the plasma SAR408701 concentration versus time curve calculated using the trapezoidal method from time 0 to 14 days (AUC0-14d) after SAR408701 1st infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK - Ctrough of SAR408701</measure>
    <time_frame>Baseline up to cycle 13 (each cycle= 2 weeks)</time_frame>
    <description>Concentration observed of SAR408701 just before SAR408701 treatment administration during repeated dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of ramucirumab</measure>
    <time_frame>Baseline to cycle 7 (each cycle= 2 weeks)</time_frame>
    <description>Concentration observed of ramucirumab just before ramucirumab treatment administration during repeated dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATAs) against SAR408701</measure>
    <time_frame>Baseline up to end of treatment (approximately 6 months)</time_frame>
    <description>Incidence of anti-therapeutic antibodies (ATAs) against SAR408701.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + SAR408701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR408701</intervention_name>
    <description>Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion</description>
    <arm_group_label>Ramucirumab + SAR408701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramucirumab</intervention_name>
    <description>Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion</description>
    <arm_group_label>Ramucirumab + SAR408701</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Histologically or cytologically proven diagnosis of non-squamous NSCLC with metastatic
             disease progression

               1. After one prior line of chemotherapy in a metastatic setting. Development of
                  metastatic disease during or within 6 months of an adjuvant/neoadjuvant treatment
                  (to be considered as first-line treatment).

               2. After or during one platinum-based chemotherapy and one immune checkpoint
                  inhibitor (whatever the order).

          -  Participants with carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 5
             expression of ≥2+ in archival tumor sample (or if not available, fresh biopsy sample)
             involving at least 50 % of the tumor cell population as demonstrated prospectively by
             central laboratory via immune histochemistry (IHC).

          -  At least one measurable lesion by RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  A female participant who agrees to use effective contraceptive methods during and for
             at least 7 months after the last dose of study intervention.

          -  A male participant who agrees to use effective contraception methods during and for at
             least 4 months after the last dose of study intervention

          -  Signed informed consent

        Exclusion criteria:

        Participants are excluded from the study if any of the following criteria apply:

          -  Patients with untreated brain metastases and history of leptomeningeal disease.

          -  Significant concomitant illnesses that would impair the patient's participation in the
             study or interpretation of the results.

          -  History within the last 3 years of an invasive malignancy other than the one treated
             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma
             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured
             by local treatment.

          -  Non-resolution of any prior treatment related toxicity to &lt; grade 2 according to NCI
             CTCAE V5.0, except for alopecia, vitiligo and active thyroiditis controlled with
             hormonal replacement therapy

          -  History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known
             HIV disease requiring antiretroviral treatment, or unresolved viral hepatitis

          -  Previous history of and/or unresolved corneal disorders. The use of contact lenses is
             not permitted.

          -  Radiographic evidence of major airway or blood vessel invasion or intratumor
             cavitation

          -  History of uncontrolled hereditary or acquired thrombotic disorder or history of
             aneurism.

          -  Major surgery within 28 days prior to Day 1/first IMP infusion,. Postoperative
             bleeding complications or wound complications from a surgical procedure performed in
             the last 2 months.

          -  History of gross hemoptysis within 2 months before the first administration of study
             intervention.

          -  Clinically relevant congestive heart failure (CHF; New York Heart Association [NYHA]
             II-IV) or symptomatic or poorly controlled cardiac arrhythmia.

          -  Any arterial thrombotic event within 6 months before the first administration of study
             intervention.

          -  Uncontrolled arterial hypertension (systolic ≥150 mmHg or diastolic ≥90 mmHg) despite
             standard medical management.

          -  Serious or nonhealing wound, skin ulcer, or bone fracture within 28 days before the
             first administration of study intervention.

          -  Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to first
             administration of study intervention.

          -  Significant bleeding disorders, vasculitis, or Grade 3-4 gastrointestinal (GI)
             bleeding within 3 months before the first administration of study intervention.

          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive
             intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea.

          -  Medical condition requiring concomitant administration of a medication with a narrow
             therapeutic window and metabolized by CYP450 or a strong CYP3A inhibitor

          -  Concurrent treatment with any other anticancer therapy

          -  No more than 1-line previous chemotherapy in metastatic setting

          -  Prior treatment with ramucirumab or docetaxel

          -  Prior therapy targeting CEACAM5 or maytansinoid treatment (DM1 or DM4 antibody-drug
             conjugate)

          -  Contraindication to use of corticosteroid premedication

          -  Current therapeutic anticoagulation with warfarin, low-molecular-weight heparin, or
             similar agents. Patients receiving prophylactic, low-dose anticoagulation therapy are
             eligible

          -  Previous enrollment in this study, current participation in any other clinical study
             involving an investigational study treatment, or any other type of medical research

          -  Poor bone marrow, liver or kidney functions

          -  Urine dipstick or routine analysis indicating proteinuria of 2+ or higher, unless a 24
             hour urine collection demonstrates &lt;1000 mg of protein.

          -  Sensitivity to any of the study interventions, or components thereof, or drug or other
             allergy that, in the opinion of the Investigator, contraindicates participation in the
             study.Most important exclusion criteria for potential participants

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

